What Assessment to Measure Prestroke Disability Must Be Completed by the Stroke Team When Determining Eligibility for Mechanical Thrombectomy: The mRS, Collateral Data, and the 6-Second Exam

The prestroke disability assessment that must be completed before mechanical thrombectomy eligibility is the modified Rankin Scale (mRS), established from the patient's historical baseline rather than their current deficit. Stroke teams reconstruct this baseline from family interview, chart review, and prior clinical records, then combine it with baseline imaging and the current NIHSS. Most US comprehensive stroke centers treat a prestroke mRS of 0–1 as clearly eligible and 2 as selectively eligible, with higher scores requiring individualized multidisciplinary judgment.

The mRS is a functional scale, not a neurologic one

The modified Rankin Scale grades global disability on a 0–6 ordinal scale. Zero means no symptoms. One means no significant disability despite symptoms. Two means slight disability: the patient manages their own affairs but cannot carry out all previous activities. Three means moderate disability requiring some help but independent walking. Four means moderately severe disability: unable to walk or attend to bodily needs without assistance. Five means severe disability: bedridden, incontinent, requiring constant care. Six means death.

The scale measures what a person could do before the stroke, not what the stroke has taken away. That distinction matters because the NIHSS measures the acute deficit and says nothing about baseline function. A patient with an NIHSS of 18 and a prestroke mRS of 0 may be an excellent thrombectomy candidate. A patient with an NIHSS of 8 and a prestroke mRS of 4 may not be.

The mRS is coarse by design. Each single-point step represents a meaningful change in independence, which is why trials and guidelines use it as the primary outcome. The coarseness is also its weakness: adjacent grades can be clinically ambiguous, and inter-rater agreement on retrospective scoring is only moderate.

Why baseline function drives the eligibility decision

Mechanical thrombectomy restores perfusion to ischemic penumbra, but it cannot restore neurons that were never there to save. Prestroke disability indexes how much functional reserve the brain had before occlusion. A patient who was already dependent has less reserve to lose and less to gain from reperfusion.

The mechanism runs through both benefit and harm. On the benefit side, functional independence at 90 days is the usual trial endpoint, and a patient who starts at mRS 3 cannot reach mRS 0–1 regardless of reperfusion. On the harm side, procedural risk, contrast exposure, sedation, and hemorrhage risk are fixed costs that a frail or dependent patient absorbs with less margin.

Baseline disability also correlates with frailty, comorbidity burden, and polypharmacy. These variables influence recanalization success and post-procedure recovery trajectories independently of the clot itself. The prestroke mRS is therefore a proxy for physiologic reserve as much as a functional snapshot.

What the numbers actually show

The pivotal trials that established thrombectomy excluded patients with prestroke mRS above 1 in most cases. HERMES pooled analysis of five trials, published in 2016, reported a number needed to treat of roughly 2.6 for reduced disability at 90 days in the overall population (Goyal et al., Lancet 2016). That figure applies to the trial-eligible population, not to all-comers.

Observational data in patients with prestroke mRS of 2 or greater suggest attenuated but nonzero benefit. Registry studies generally show lower rates of functional independence and higher mortality in this group, with wide confidence intervals. The signal is directionally favorable in selected patients and does not support a blanket exclusion.

Guidelines reflect the evidence gap. The 2019 AHA/ASA guideline update for early management of acute ischemic stroke supports thrombectomy in patients with prestroke mRS of 0–1 and recommends individualized consideration for higher scores (Powers et al., Stroke 2019). Later updates have not moved to a firm higher-score threshold.

The number that matters at the bedside is not a single cutoff but the probability of meaningful functional gain. A prestroke mRS of 2 with a large penumbra and a favorable time window may offer more absolute benefit than an mRS of 0 with a completed infarct and no salvageable tissue.

Reconstructing the baseline is the hard part

Most stroke patients cannot report their own baseline. Aphasia, sedation, intubation, and acute confusion all block direct history. The stroke team must triangulate from three sources.

The first is collateral history from a family member or caregiver who knows the patient's daily function. The second is chart review: primary care notes, nursing home records, prior admission documentation, and medication lists. The third is the physical examination, which can reveal contractures, muscle wasting, prior surgical changes, and assistive devices that imply baseline limitation.

The counterintuitive detail: a clean NIHSS in a patient with known baseline dementia does not mean the patient is functionally intact. The NIHSS was designed to capture acute stroke deficits, and it systematically underweights cognitive, gait, and self-care impairment. Teams that rely on NIHSS alone will overestimate baseline independence.

Red flags that baseline function is being overestimated:

No collateral historian available and no records retrieved within the treatment window. Patient arrives from a nursing facility without transfer documentation. Chart shows prior stroke with residual deficit but no documented mRS. Family reports recent functional decline that predates the current symptom onset. Sedation or intubation prevents any meaningful neurologic examination.

When baseline cannot be reconstructed, document the uncertainty explicitly and treat the decision as a shared one. Some centers involve a second attending or a rapid ethics-adjacent huddle for borderline cases.

Comparison table: baseline assessment tools

The mRS occupies the primary role because trials and guidelines are built around it. The other tools inform the individualized judgment at higher scores.

Timing: when the baseline assessment must be done

The assessment must be complete before the treatment decision is finalized, which in practice means within the imaging-to-groin interval. Every minute of delay reduces the probability of good outcome, so the baseline history runs in parallel with imaging rather than after it.

These windows describe typical high-volume workflows and are not universal mandates. The underlying principle is that baseline assessment should never be the rate-limiting step.

Misconceptions that distort eligibility decisions

The most common misconception is that a high prestroke mRS automatically disqualifies a patient. Guidelines do not support automatic exclusion, and registry data do not show uniform futility. The decision is individualized, and documentation should reflect that.

A second misconception is that the NIHSS substitutes for the mRS. It does not. A patient with severe aphasia and an NIHSS of 20 may have been completely independent before the stroke, while a patient with a modest NIHSS of 5 may have been dependent for years.

A third misconception is that family report is unreliable and therefore unusable. Family report is imperfect, but it is more accurate than no baseline at all and can be cross-checked against records. Teams that discard family history systematically will make worse decisions in patients without retrievable records.

A fourth misconception is that a low prestroke mRS guarantees benefit. Time window, infarct volume, collateral status, and clot location all modulate benefit independently. The mRS gates eligibility; it does not predict outcome on its own.

Practical actions for the stroke team

Assign a named team member to baseline history at activation. The role should be explicit in the stroke protocol, not assumed. In most centers this falls to a stroke nurse or advanced practice provider working in parallel with the imaging team.

Use a structured interview script that walks through each mRS grade with concrete examples. Unscripted family interviews systematically produce lower disability estimates because families anchor on the patient's best days rather than typical function.

Request records proactively for any patient with a known nursing facility residence, prior stroke, dementia diagnosis, or recent hospitalization. Electronic health record alerts and health information exchange queries can often retrieve baseline data within the treatment window.

Document the source of the baseline estimate. State whether it came from family, records, examination, or a combination, and note any uncertainty. This documentation supports both clinical audit and downstream outcome research.

Reconcile thresholds explicitly. If the patient's prestroke mRS is 2, document why the team judged the patient eligible or ineligible. If it is 3 or higher, document the individualized reasoning and any second-opinion consultation.

Escalate borderline cases to a second attending when time allows. A structured huddle of two clinicians can reduce anchoring bias and improve documentation quality.

Limitations and what the evidence does not settle

The evidence base for prestroke mRS above 2 is observational. No randomized trial has established a definitive benefit threshold in this population, and the confidence intervals around reported effects are wide. Experts disagree on whether the correct analytic approach is a cutoff, a continuous interaction, or a risk-benefit model.

The mRS itself has psychometric limits. Retrospective scoring from collateral history has only moderate inter-rater reliability, and the scale conflates physical and cognitive disability in ways that may misclassify patients with baseline cognitive impairment but preserved mobility.

Institutions vary in how they operationalize the assessment. Some use a strict mRS of 0–1 threshold, others extend to 2 with imaging and comorbidity criteria, and still others defer to individualized judgment across the full range. There is no single national standard beyond the guideline language.

These gaps are not a reason to skip the assessment. They are a reason to document it carefully and to treat borderline cases with explicit reasoning rather than implicit bias.

This article is general educational information about stroke team assessment practices, not a diagnosis, treatment plan, or substitute for clinical judgment. It does not guarantee any outcome from mechanical thrombectomy or any other intervention. Clinicians should follow local protocols, current society guidelines, and consultation with qualified colleagues for individual patient decisions. Patients and families should direct questions about eligibility and treatment to the treating stroke team or a qualified local physician.